Release Notes: Version 20230509
About this release
This release (version 20230509) provides the latest updates to the Canadian Clinical Drug Data Set in English and French. A separate InfoScribe location for the French supporting documents, including the French Release Notes, can be found here.
There is no change to the Technical Specification or the Editorial Guidelines.
The Canadian Clinical Drug Data Set is available for browsing and download via the Infoway Terminology Gateway.
Supporting general information can be found on Infoway Canadian Clinical Drug Data Set InfoCentral page.
General Notes
The following files are available as full release files within this version:
- Manufactured Product,
- Non-proprietary Therapeutic Product,
- Therapeutic Moiety,
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in English (MP-NTP-TM Relationship),
- Manufactured Product-Non-proprietary Therapeutic Product-Therapeutic Product Relationship, in French (Relation PM-PTC-FT),
- Special Groupings,
- Coded Attribute, and
- Device Non-proprietary Therapeutic Product.
The "Full" release contains one entry for every concept that has ever been released and new content added for that release. New content added for a specific release may at times include “Inactive” content.
NOTE: The “Delta" release which is intended to contain only those concepts that have been added or changed since the previous release will be considered for a future enhancement at a later date.
This release reflects additions and changes that have occurred in DPD since the last CCDD release.
Non-proprietary Therapeutic Product (NTP)
There is 1 new deprecated concept in this version resulting from a change in strength in DPD. The stated strength of the associated product has changed from the dose released per actuation to the dose delivered per actuation.
ntp_code | ntp_formal_name | ntp_fr_description | Change | New ntp_code | New ntp_formal_name | New ntp_fr_description |
|---|---|---|---|---|---|---|
9014634 | budesonide 182 mcg per actuation and formoterol fumarate 5.8 mcg per actuation and glycopyrronium (glycopyrronium bromide) 8.2 mcg per actuation pressurized inhalation | budésonide 182 mcg par actionnement et fumarate de formotérol 5,8 mcg par actionnement et glycopyrronium (bromure de glycopyrronium) 8,2 mcg par actionnement inhalation en flacon pressurisé | Deprecated | 9014844 | budesonide 160 mcg per actuation and formoterol fumarate 5 mcg per actuation and glycopyrronium (glycopyrronium bromide) 7.2 mcg per actuation pressurized inhalation | budésonide 160 mcg par actionnement et fumarate de formotérol 5 mcg par actionnement et glycopyrronium (bromure de glycopyrronium) 7,2 mcg par actionnement inhalation en flacon pressurisé |
Manufactured Product (MP)
The following MP formal name change has occurred resulting in the newly deprecated NTP shown above.
mp_code | mp_formal_name April Release | mp_fr_description April Release | mp_formal_name (new) May Release | mp_fr_description (new) May Release |
|---|---|---|---|---|
| 02518058 | BREZTRI AEROSPHERE (budesonide 182 mcg per actuation and formoterol fumarate dihydrate 5.8 mcg per actuation and glycopyrronium (glycopyrronium bromide) 8.2 mcg per actuation pressurized inhalation) ASTRAZENECA CANADA INC | BREZTRI AEROSPHERE (budésonide 182 mcg par actionnement et fumarate de formotérol dihydraté 5,8 mcg par actionnement et glycopyrronium (bromure de glycopyrronium) 8,2 mcg par actionnement inhalation en flacon pressurisé) ASTRAZENECA CANADA INC | BREZTRI AEROSPHERE (budesonide 160 mcg per actuation and formoterol fumarate dihydrate 5 mcg per actuation and glycopyrronium (glycopyrronium bromide) 7.2 mcg per actuation pressurized inhalation) ASTRAZENECA CANADA INC | BREZTRI AEROSPHERE (budésonide 160 mcg par actionnement et fumarate de formotérol dihydraté 5 mcg par actionnement et glycopyrronium (bromure de glycopyrronium) 7,2 mcg par actionnement inhalation en flacon pressurisé) ASTRAZENECA CANADA INC |
Questions, Concerns, Changes
Questions and concerns and suggestions for future consideration are welcomed and should be sent by e-mail at [email protected]